Gregory Allen Davis

US Patent:

20210388396, Dec 16, 2021

Filed:

Aug 10, 2021

Appl. No.:

17/398648

Inventors:

- St. Louis MO, US
Gregory D. Davis - Berkeley CA, US

International Classification:

C12N 15/90
C12N 9/22
C12N 15/63
C12N 15/10
C12N 15/85
C07K 7/06
C12N 15/11
C12N 7/00
C12N 15/67
C12N 15/86
C07K 14/46
C12N 9/96

Abstract:

The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.

US Patent:

20210207165, Jul 8, 2021

Filed:

Mar 22, 2021

Appl. No.:

17/208477

Inventors:

- St. Louis MO, US
Gregory Davis - Berkeley CA, US

International Classification:

C12N 15/85
C12N 9/22
C12N 15/90

Abstract:

The present invention provides methods for modifying chromosomal sequences. In particular, methods are provided for using RNA-guided endonucleases or modified RNA-guided endonucleases to modify targeted chromosomal sequences.

US Patent:

20210207173, Jul 8, 2021

Filed:

Jul 30, 2020

Appl. No.:

16/943767

Inventors:

- St. Louis MO, US
Gregory D. Davis - Berkeley CA, US

International Classification:

C12N 15/90
C12N 9/22
C12N 15/63
C12N 15/10
C12N 15/85
C07K 7/06
C12N 15/11
C12N 7/00
C12N 15/67
C12N 15/86
C07K 14/46
C12N 9/96

Abstract:

The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.

US Patent:

20210079427, Mar 18, 2021

Filed:

Jul 30, 2020

Appl. No.:

16/943792

Inventors:

- St. Louis MO, US
Gregory D. Davis - Berkeley CA, US

International Classification:

C12N 15/90
C12N 9/22
C12N 15/63
C12N 15/10
C12N 15/85
C07K 7/06
C12N 15/11
C12N 7/00
C12N 15/67
C12N 15/86
C07K 14/46
C12N 9/96

Abstract:

The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.

US Patent:

20200354752, Nov 12, 2020

Filed:

Jul 30, 2020

Appl. No.:

16/943813

Inventors:

- St. Louis MO, US
Fuqiang Chen - St. Louis MO, US
Gregory D. Davis - Berkeley CA, US

International Classification:

C12N 15/90
C12N 15/113
C12N 9/22
C12N 15/85
C12N 15/10

Abstract:

Engineered Cas9 systems that utilize alternate protospacer adjacent motifs for target DNA binding, nucleic acids encoding the engineered Cas9 systems, and methods of using the engineered Cas9 systems for modifying target chromosomal sequences in eukaryotic cells.